Devonian Health Group Announces Presentation of Thykamine Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides Thykamine Clinical Development Program Update.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that results from phase 2 clinical study in mild-to-moderate atopic dermatitis (‘‘AD’’) will be presented at the upcoming 25th World Congress of Dermatology (‘‘WCD’’) to be held in Singapore from July 3rd to 8th. Results from the study will be made available on Devonian’s website following the poster presentation at WCD by Dr. Charles Lynde (Associate Professor, University of Toronto, Department of Medicine) at https://www.groupedevonian.com/investor-center/corporate-presentation.

Poster: Phase 2 trial of a Novel Botanical Topical Anti-Inflammatory Drug, in adults with Mild-to-Moderate Atopic Dermatitis. This poster summarizes results from the phase 2 clinical study in adult patients with mild-to-moderate atopic dermatitis. In the study, the efficacy of Thykamine cream was comparable to other non-steroidal topical therapies approved for the treatment of mild-to-moderate AD, while demonstrating a favorable safety and tolerability profile.

Thykamine Clinical Development Program Update

Devonian also provided an update on its Thykamine program activities in advance of the WCD Meeting. To support the clinical program of Thykamine, the company is establishing its final formulation manufacturing activities in a leading global contract development and manufacturing. The transfer and validation process should be completed within the next months. Devonian will then, as a priority, file to regulatory agencies a phase 2/3 protocol in pediatric patient population with mild-to-moderate atopic dermatitis. As second and third priorities, the corporation expects to file a phase2 clinical study protocol in radiodermatitis associated to radiotherapy and a phase 2 clinical study in Hand and Foot Syndrome associated to chemotherapy.

“We are thrilled to see the vast potential of Thykamine as a novel treatment option for pediatric patients with atopic dermatitis and other skin inflammatory conditions” commented Mr Pierre Montanaro, President and Chief Executive Officer of the Corporation. “While our focus is on pediatric patient population suffering of Atopic dermatitis, there are clearly unmet medical needs for cancer patients with chemotherapy-related Hand and Foot Syndrome as well as for patients with radiotherapy-related radiodermatitis¹. We believe that Thykamine could be an effective therapeutic for these physical skin changes associated to cancer therapies and help improve patients Quality of Life” added Mr. Montanaro.